Apollomics logo

Apollomics Share Price Today

(NASDAQ: APLM)

Apollomics share price is $7.08 & ₹615.40 as on 19 Feb 2025, 2.30 'hrs' IST

$7.08

-0.03

(-0.42%)

Market is closed - opens 8 PM, 19 Feb 2025

View live Apollomics share price in Dollar and Rupees. Guide to invest in Apollomics stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Apollomics, along with analyst recommendations, forecasts, and comprehensive financials.

Apollomics share price movements

  • Today's Low: $6.86
    Today's High: $7.57

    Day's Volatility :9.38%

  • 52 Weeks Low: $6.38
    52 Weeks High: $80.50

    52 Weeks Volatility :92.07%

Apollomics (APLM) Returns

PeriodApollomics IncIndex (Russel 2000)
3 Months
-52.54%
0.0%
6 Months
-45.73%
0.0%
1 Year
-89.08%
0.0%
3 Years
-99.76%
-12.0%

Apollomics (APLM) Key Statistics

in dollars & INR

Previous Close
$7.11
Open
$7.57
Today's High
$7.57
Today's Low
$6.86
Market Capitalization
$16.5M
Today's Volume
$6.2K
52 Week High
$80.5
52 Week Low
$6.38
Revenue TTM
$2.1M
EBITDA
$-53.1M
Earnings Per Share (EPS)
$-0.15
Profit Margin
0.0%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-149.31%

How to invest in Apollomics Stock (APLM) from India?

It is very easy for Indian residents to invest directly in Apollomics from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Apollomics stock in both Indian Rupees (INR) and US Dollars (USD). Search for Apollomics or APLM on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Apollomics or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Apollomics shares which would translate to 0.123 fractional shares of Apollomics as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Apollomics, in just a few clicks!

Returns in Apollomics (APLM) for Indian investors in Rupees

The Apollomics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Apollomics investment value today

Current value as on today

₹15,725

Returns

₹84,275

(-84.28%)

Returns from Apollomics Stock

₹89,124 (-89.12%)

Dollar Returns

₹4,849 (+4.85%)

Indian investors sentiment towards Apollomics (APLM)

-52%

Period: Jan 19, 2025 to Feb 18, 2025. Change in 30 Days versus previous period

Search interest for Apollomics Stock from India on INDmoney has decreased by -52% in the last 30 days, reflecting a downward trend in search activity.

Analyst Recommendation on Apollomics

Buy

    87%Buy

    12%Hold

    0%Sell

Based on 8 Wall street analysts offering stock ratings for Apollomics(by analysts ranked 0 to 5 stars)

Based on 8 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
7
7
7
Hold
1
1
1
Sell
0
0
0

Analyst Forecast on Apollomics Stock (APLM)

What analysts predicted

Downside of 71.75%

Target:

$2.00

Current:

$7.08

Insights on Apollomics Stock (Ticker Symbol: APLM)

  • Price Movement

    In the last 1 month, APLM stock has moved down by -25.6%
  • APLM vs ALNY (1 yr)

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 74.5% return, outperforming this stock by 163.0%
  • Price to Sales

    ForAPLM every $1 of sales, investors are willing to pay $307.8, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $14.2 for every $1 of sales.

Apollomics Technicals Summary

Sell

Neutral

Buy

Apollomics is currently in a neutral trading position according to technical analysis indicators.

Apollomics (APLM) Vs Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Apollomics Inc logo
-25.32%
-45.73%
-89.08%
-99.76%
-99.76%
Biontech Se logo
2.2%
34.66%
31.33%
-20.05%
270.42%
Regeneron Pharmaceuticals, Inc. logo
-2.06%
-43.17%
-28.86%
11.73%
67.08%
Vertex Pharmaceuticals Incorporated logo
7.27%
-5.58%
9.12%
99.38%
86.37%
Alnylam Pharmaceuticals, Inc. logo
-3.22%
-8.14%
71.32%
74.68%
95.72%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Apollomics Inc logo
NA
NA
NA
0.0
-1.49
-0.63
NA
0.19
Biontech Se logo
160.8
NA
0.04
-3.29
-0.02
-0.01
NA
79.73
Regeneron Pharmaceuticals, Inc. logo
17.57
17.57
0.99
43.2
0.16
0.07
NA
273.57
Vertex Pharmaceuticals Incorporated logo
32.84
NA
1.27
18.13
-0.03
0.13
NA
63.87
Alnylam Pharmaceuticals, Inc. logo
NA
NA
-0.49
0.84
-15.01
-0.03
NA
0.52
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Apollomics Inc logo
Buy
$16.5M
-99.76%
NA
0.0%
Biontech Se logo
Buy
$28.7B
270.42%
160.8
-15.36%
Regeneron Pharmaceuticals, Inc. logo
Buy
$73.6B
67.08%
17.57
31.07%
Vertex Pharmaceuticals Incorporated logo
Buy
$117.9B
86.37%
32.84
-4.86%
Alnylam Pharmaceuticals, Inc. logo
Buy
$33.2B
95.72%
NA
-12.37%

About Apollomics

Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer; APL-102, an oral active, small molecule Multiple Tyrosine Kinase Inhibitor, which is in a in a Phase 1 clinical trial to inhibit various kinases that are aberrantly activated in cancer cells; and APL-122, a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathwaysthat is in Phase 1 dose escalation clinical trials to treat cancers within the brain. Its also developing uproleselan (APL-106) that is in Phase 3 clinical trial for the treatment of adult patients with relapsed or refractory AML, as well as Phase 2/3 study with uproleselan for the treatment of newly diagnosed older adults with AML; and APL-108, a second-generation E-selective inhibitor, which has completed Phase 1 clinical trials to treat other liquid and solid cancers. The company's pipeline consists of preclinical stage immuno-oncology product candidates, such as APL-501, APL-502, APL-801 and APL-810. Its solutions include tumor inhibitors, anti-cancer enhancers, and immune-oncology drugs. Apollomics, Inc. was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. The company was incorporated in 2015 and is based in Foster City, California.
Organization
Apollomics
Employees
45
CEO
Dr. Guo-Liang Yu Ph.D.
Industry
Miscellaneous

Management People of Apollomics

NameTitle
Dr. Guo-Liang Yu Ph.D.
Co-Founder, CEO & Executive Chairman
Dr. Matthew James Plunkett Ph.D.
Chief Financial Officer

Important FAQs about investing in APLM Stock from India :

What is Apollomics share price today?

Apollomics share price today stands at $7.08, Open: $7.57 ; Previous Close: $7.11 ; High: $7.57 ; Low: $6.86 ; 52 Week High: $80.50 ; 52 Week Low: $6.38.

The stock opens at $7.57, after a previous close of $7.11. The stock reached a daily high of $7.57 and a low of $6.86, with a 52-week high of $80.50 and a 52-week low of $6.38.

Can Indians buy Apollomics shares?

Yes, Indians can invest in the Apollomics (APLM) from India.

With INDmoney, you can buy Apollomics at 0 brokerage. The step-by-step process is as follows:

  • Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
  • Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
  • Once funds are transferred successfully, you can buy Apollomics at zero transaction cost.

How can I buy Apollomics shares from India?

It is very easy to buy Apollomics from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Apollomics (APLM) be purchased?

Yes, you can buy fractional shares of Apollomics with INDmoney app.

What are the documents required to start investing in Apollomics stocks?

To start investing in Apollomics, You will need the following documents:

  • Proof of Identification (PAN, Aadhaar etc)
  • Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What are today’s High and Low prices of Apollomics Stock (APLM)?

Today’s highest price of Apollomics (APLM) is $7.57.

Today’s lowest price of Apollomics (APLM) is $6.86.

What is today's market capitalisation of Apollomics?

Today's market capitalisation of Apollomics APLM is 16.5M

What is the 52 Week High and Low Range of Apollomics Stock (APLM)?

  • 52 Week High

    $80.50

  • 52 Week Low

    $6.38

What are the historical returns of Apollomics (APLM)?

  • 1 Month Returns

    -25.32%

  • 3 Months Returns

    -45.73%

  • 1 Year Returns

    -89.08%

  • 5 Years Returns

    -99.76%

Who is the Chief Executive Officer (CEO) of Apollomics ?

Dr. Guo-Liang Yu Ph.D. is the current Chief Executive Officer (CEO) of Apollomics.